董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susannah Gray | 女 | Independent Director | 66 | 未披露 | 未持股 | 2026-09-21 |
| John Orwin | 男 | Chairman of the Board | 61 | 37.02万美元 | 6.72 | 2026-09-21 |
| Daniel Faga | 男 | Chief Executive Officer,Director and President | 46 | 613.39万美元 | 104.16 | 2026-09-21 |
| Hollings Renton | 男 | Independent Director | 79 | 32.02万美元 | 11.56 | 2026-09-21 |
| John P. Schmid | 男 | Independent Director | 63 | 33.70万美元 | 14.22 | 2026-09-21 |
| Oleg Nodelman | 男 | Independent Director | 49 | 未披露 | 788.01 | 2026-09-21 |
| Owen Hughes | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-09-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Faga | 男 | Chief Executive Officer,Director and President | 46 | 613.39万美元 | 104.16 | 2026-09-21 |
| Christopher M. Murphy | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2026-09-21 |
董事简历
中英对照 | 中文 | 英文- Susannah Gray
-
Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University. - Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
- Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University.
- John Orwin
-
John Orwin，自2022年9月起担任Cargo Therapeutics，Inc.董事会主席。自2018年4月起，奥文先生担任上市生物制药公司Atreca, Inc.的总裁兼首席执行官。2013年至2017年，Orwin先生担任Relypsa, Inc.的总裁兼首席执行官，该公司是一家生物制药公司，于2016年被Galenica AG收购。在此之前，2010年至2011年，Orwin先生担任上市生物技术公司Affymax, Inc.的总裁兼首席执行官。2005年至2010年，Orwin先生担任基因泰克生物肿瘤业务部门副总裁，后来又担任高级副总裁。Genentech是一家私有生物技术公司，也是罗氏集团的成员。Orwin先生目前担任Atreca, Inc.、Travere Therapeutics公司和Seagen公司的董事会成员。Orwin先生以前曾担任Affymax公司的董事会成员。公司、Array BioPharma公司、Relypsa公司和NeurogesX公司。Orwin先生在罗格斯大学获得经济学学士学位，在纽约大学Leonard M. Stern商学院获得工商管理硕士学位。
John Orwin has served as a member of Anaptysbio, Inc.'s Board and Chairman of Anaptysbio, Inc.'s Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of the publicly traded First Tracks Biotherapeutics, Inc., a pharmaceutical company, Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University. - John Orwin，自2022年9月起担任Cargo Therapeutics，Inc.董事会主席。自2018年4月起，奥文先生担任上市生物制药公司Atreca, Inc.的总裁兼首席执行官。2013年至2017年，Orwin先生担任Relypsa, Inc.的总裁兼首席执行官，该公司是一家生物制药公司，于2016年被Galenica AG收购。在此之前，2010年至2011年，Orwin先生担任上市生物技术公司Affymax, Inc.的总裁兼首席执行官。2005年至2010年，Orwin先生担任基因泰克生物肿瘤业务部门副总裁，后来又担任高级副总裁。Genentech是一家私有生物技术公司，也是罗氏集团的成员。Orwin先生目前担任Atreca, Inc.、Travere Therapeutics公司和Seagen公司的董事会成员。Orwin先生以前曾担任Affymax公司的董事会成员。公司、Array BioPharma公司、Relypsa公司和NeurogesX公司。Orwin先生在罗格斯大学获得经济学学士学位，在纽约大学Leonard M. Stern商学院获得工商管理硕士学位。
- John Orwin has served as a member of Anaptysbio, Inc.'s Board and Chairman of Anaptysbio, Inc.'s Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of the publicly traded First Tracks Biotherapeutics, Inc., a pharmaceutical company, Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University.
- Daniel Faga
-
Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
Daniel Faga has served as a member of Anaptysbio, Inc.'s Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. - Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
- Daniel Faga has served as a member of Anaptysbio, Inc.'s Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.
- Hollings Renton
-
Hollings Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
Hollings Renton has served as a member of Anaptysbio, Inc.'s Board since June 2015. Mr. Renton previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of its board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr. Renton served as the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from 1991 to 1993, following its acquisition of Cetus Corporation. Mr. Renton served as the President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton previously served on the board of directors of Zymeworks, Inc., a publicly traded company, from 2017 to 2024, and Portola Pharmaceuticals, Inc., a publicly traded company, from March 2010 to June 2020. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. - Hollings Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
- Hollings Renton has served as a member of Anaptysbio, Inc.'s Board since June 2015. Mr. Renton previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of its board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr. Renton served as the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from 1991 to 1993, following its acquisition of Cetus Corporation. Mr. Renton served as the President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton previously served on the board of directors of Zymeworks, Inc., a publicly traded company, from 2017 to 2024, and Portola Pharmaceuticals, Inc., a publicly traded company, from March 2010 to June 2020. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.
- John P. Schmid
-
John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
John P. Schmid has served as a member of Anaptysbio, Inc.'s Board since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at Gene Formatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of the publicly traded company Design Therapeutics Inc., a pharmaceutical company, First Tracks Biotherapeutics, Inc., a publicly traded pharmaceutical company, Bright Peak Therapeutics, a private biotechnology company, and BlossomHill Therapeutics, Inc., a private pharmaceutical company. In the last five years, Mr. Schmid has previously served on the boards of directors of Helix Acquisition Corp. and Helix Acquisition Corp. II, both special purpose acquisition companies, Neos Therapeutics, Poseida Therapeutics, Inc., and Xeris Pharmaceuticals, all pharmaceutical companies. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University. - John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
- John P. Schmid has served as a member of Anaptysbio, Inc.'s Board since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at Gene Formatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of the publicly traded company Design Therapeutics Inc., a pharmaceutical company, First Tracks Biotherapeutics, Inc., a publicly traded pharmaceutical company, Bright Peak Therapeutics, a private biotechnology company, and BlossomHill Therapeutics, Inc., a private pharmaceutical company. In the last five years, Mr. Schmid has previously served on the boards of directors of Helix Acquisition Corp. and Helix Acquisition Corp. II, both special purpose acquisition companies, Neos Therapeutics, Poseida Therapeutics, Inc., and Xeris Pharmaceuticals, all pharmaceutical companies. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University.
- Oleg Nodelman
-
Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
Oleg Nodelman has served as a member of Anaptysbio, Inc.'s Board since April 2021 and will be Chairman of Anaptysbio, Inc.'s Board effective immediately following the Annual Meeting. Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech focused investment advisory firm established in 2013, and one of Anaptysbio, Inc.'s principal stockholders, since its inception. Previously, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman currently serves on the board of directors of both Galapagos NV and Zymeworks, and previously served on the board of directors of Prothena Corporation plc from 2019 to 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021. - Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
- Oleg Nodelman has served as a member of Anaptysbio, Inc.'s Board since April 2021 and will be Chairman of Anaptysbio, Inc.'s Board effective immediately following the Annual Meeting. Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech focused investment advisory firm established in 2013, and one of Anaptysbio, Inc.'s principal stockholders, since its inception. Previously, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman currently serves on the board of directors of both Galapagos NV and Zymeworks, and previously served on the board of directors of Prothena Corporation plc from 2019 to 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021.
- Owen Hughes
-
Owen Hughes还是一家肿瘤治疗公司Cullinan Oncology，LLC的总裁、首席执行官兼董事，自2017年9月起担任该公司总裁。在加入Cullinan Oncology之前，Hughes先生于2013年2月至2017年9月在生物制药公司Intarcia Therapeutics，Inc.担任首席业务官和企业发展主管。休斯此前曾担任贝恩资本对冲基金Brookside Capital Investors，L.P.的董事，以及富达投资公司Pyramis Global Advisors LLC的高级投资组合经理。他还担任Radius Health, Inc.纳斯达克：RDUS的董事长以及Translate Bio, Inc.（纳斯达克）和Wren Therapeutics，Inc.的董事。在过去五年中，他还曾在Malin Corporation PLC的董事会任职。休斯先生获得了达特茅斯学院的历史学学士学位。
Owen Hughes is also President, Chief Executive Officer and director of Cullinan Oncology, LLC, an oncology therapeutics company, since September 2017. Prior to joining Cullinan Oncology, Mr. Hughes served as the Chief Business Officer and head of Corporate Development at Intarcia Therapeutics, Inc., a biopharmaceutical company, from February 2013 to September 2017. Mr. Hughes previously acted as Director at Brookside Capital Investors, L.P., a Bain Capital hedge fund, and Senior Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments company. He also serves as Chairman of Radius Health, Inc. Nasdaq: RDUS and as a director of Translate Bio, Inc. (Nasdaq: TBIO) and Wren Therapeutics, Inc. In the past five years, he also served on the board of directors of Malin Corporation plc. Mr. Hughes received a B.A. from Dartmouth College in History. - Owen Hughes还是一家肿瘤治疗公司Cullinan Oncology，LLC的总裁、首席执行官兼董事，自2017年9月起担任该公司总裁。在加入Cullinan Oncology之前，Hughes先生于2013年2月至2017年9月在生物制药公司Intarcia Therapeutics，Inc.担任首席业务官和企业发展主管。休斯此前曾担任贝恩资本对冲基金Brookside Capital Investors，L.P.的董事，以及富达投资公司Pyramis Global Advisors LLC的高级投资组合经理。他还担任Radius Health, Inc.纳斯达克：RDUS的董事长以及Translate Bio, Inc.（纳斯达克）和Wren Therapeutics，Inc.的董事。在过去五年中，他还曾在Malin Corporation PLC的董事会任职。休斯先生获得了达特茅斯学院的历史学学士学位。
- Owen Hughes is also President, Chief Executive Officer and director of Cullinan Oncology, LLC, an oncology therapeutics company, since September 2017. Prior to joining Cullinan Oncology, Mr. Hughes served as the Chief Business Officer and head of Corporate Development at Intarcia Therapeutics, Inc., a biopharmaceutical company, from February 2013 to September 2017. Mr. Hughes previously acted as Director at Brookside Capital Investors, L.P., a Bain Capital hedge fund, and Senior Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments company. He also serves as Chairman of Radius Health, Inc. Nasdaq: RDUS and as a director of Translate Bio, Inc. (Nasdaq: TBIO) and Wren Therapeutics, Inc. In the past five years, he also served on the board of directors of Malin Corporation plc. Mr. Hughes received a B.A. from Dartmouth College in History.
高管简历
中英对照 | 中文 | 英文- Daniel Faga
Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
Daniel Faga has served as a member of Anaptysbio, Inc.'s Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.- Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
- Daniel Faga has served as a member of Anaptysbio, Inc.'s Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.
- Christopher M. Murphy
Christopher M. Murphy自2026年5月起担任AnaptysBio, Inc.的首席财务官。在加入AnaptysBio, Inc.之前，Murphy先生于2024年1月至2025年12月期间担任Third Harmonic Bio公司的首席财务和业务官。在此之前，Murphy先生曾于2014年3月至2020年5月在Horizon Therapeutics PLC或Horizon担任越来越多的职务，2014年3月至2015年11月担任业务发展副总裁，2015年11月至2017年10月担任集团企业发展副总裁，2017年10月至2018年6月担任集团运营副总裁、炎症业务部门，最近于2018年6月至2020年5月担任集团商业运营和分析副总裁。在加入Horizon之前，Murphy先生于2008年7月至2014年3月在JMP Securities LLC（JMP）的生命科学投资银行集团担任越来越重要的职务，最近一次是在2014年2月至2014年3月担任董事。在加入JMP之前，Murphy先生于2006年7月至2008年6月期间担任法维翰咨询公司诉讼和调查组的顾问。Murphy先生拥有圣母大学金融学学士学位。
Christopher M. Murphy has served as Anaptysbio, Inc.'s Chief Financial Officer since May 2026. Prior to joining Anaptysbio, Inc., Mr. Murphy served as Chief Financial and Business Officer of Third Harmonic Bio, Inc. from January 2024 through December 2025. Prior to that, Mr. Murphy held positions of increasing responsibility at Horizon Therapeutics PLC, or Horizon, from March 2014 to May 2020, serving as Vice President of Business Development from March 2014 to November 2015, Group Vice President of Corporate Development from November 2015 to October 2017, Group Vice President of Operations, Inflammation Business Unit from October 2017 to June 2018, and most recently as Group Vice President, Commercial Operations and Analytics from June 2018 to May 2020. Prior to Horizon, Mr. Murphy held positions of increasing responsibility in the Life Sciences Investment Banking Group at JMP Securities LLC, or JMP, from July 2008 to March 2014, serving most recently as a Director from February 2014 to March 2014. Prior to JMP, Mr. Murphy served as a Consultant in the Litigation and Investigation Group of Navigant Consulting, Inc. from July 2006 to June 2008. Mr. Murphy holds a B.B.A. in Finance from the University of Notre Dame.- Christopher M. Murphy自2026年5月起担任AnaptysBio, Inc.的首席财务官。在加入AnaptysBio, Inc.之前，Murphy先生于2024年1月至2025年12月期间担任Third Harmonic Bio公司的首席财务和业务官。在此之前，Murphy先生曾于2014年3月至2020年5月在Horizon Therapeutics PLC或Horizon担任越来越多的职务，2014年3月至2015年11月担任业务发展副总裁，2015年11月至2017年10月担任集团企业发展副总裁，2017年10月至2018年6月担任集团运营副总裁、炎症业务部门，最近于2018年6月至2020年5月担任集团商业运营和分析副总裁。在加入Horizon之前，Murphy先生于2008年7月至2014年3月在JMP Securities LLC（JMP）的生命科学投资银行集团担任越来越重要的职务，最近一次是在2014年2月至2014年3月担任董事。在加入JMP之前，Murphy先生于2006年7月至2008年6月期间担任法维翰咨询公司诉讼和调查组的顾问。Murphy先生拥有圣母大学金融学学士学位。
- Christopher M. Murphy has served as Anaptysbio, Inc.'s Chief Financial Officer since May 2026. Prior to joining Anaptysbio, Inc., Mr. Murphy served as Chief Financial and Business Officer of Third Harmonic Bio, Inc. from January 2024 through December 2025. Prior to that, Mr. Murphy held positions of increasing responsibility at Horizon Therapeutics PLC, or Horizon, from March 2014 to May 2020, serving as Vice President of Business Development from March 2014 to November 2015, Group Vice President of Corporate Development from November 2015 to October 2017, Group Vice President of Operations, Inflammation Business Unit from October 2017 to June 2018, and most recently as Group Vice President, Commercial Operations and Analytics from June 2018 to May 2020. Prior to Horizon, Mr. Murphy held positions of increasing responsibility in the Life Sciences Investment Banking Group at JMP Securities LLC, or JMP, from July 2008 to March 2014, serving most recently as a Director from February 2014 to March 2014. Prior to JMP, Mr. Murphy served as a Consultant in the Litigation and Investigation Group of Navigant Consulting, Inc. from July 2006 to June 2008. Mr. Murphy holds a B.B.A. in Finance from the University of Notre Dame.